Trial Profile
A Phase I Pharmacologic Study of CYC140, a Polo-like Kinase 1 Inhibitor, in Patients With Advanced Leukemias or Myelodysplastic Syndromes
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 03 Apr 2024
Price :
$35
*
At a glance
- Drugs Plogosertib (Primary) ; Plogosertib (Primary)
- Indications Leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions; First in man
- Sponsors Cyclacel Pharmaceuticals
- 18 Dec 2023 According to a Cyclacel Pharmaceuticals media release, patients are being recruited at dose level 5. To date, 15 patients have been recruited at five dose escalation levels.
- 22 Apr 2022 Planned End Date changed from 28 Feb 2021 to 1 Sep 2023.
- 22 Apr 2022 Planned primary completion date changed from 26 Oct 2020 to 1 Apr 2023.